Tirzepatide
Mounjaro, Zepbound, LY3298176
A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Completed
PHASE3
NCT04184622
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT06326060
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT04311424
Study of Tirzepatide in Healthy Participants
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
NCT05756764
Anti-obesity Pharmacotherapy and Inflammation
Louisiana State University Health Sciences Center in New Orleans
OBSERVATIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT05536804
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06847399
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Johns Hopkins University
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE2
NCT06073184
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
University Health Network, Toronto
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04657016
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NCT07229170
Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients
San Raffaele Telematic University
OBSERVATIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06588283
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06802081
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
The Cleveland Clinic
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT05766358
Role Of Metabolic Adaptation In Weight Regain
Pennington Biomedical Research Center
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT07202247
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
City of Hope Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Enrolling By Invitation
NCT07179796
Digital Physical Activity Program
Sword Health, SA
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06857942
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04844918
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT06439277
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT03730662
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE2
NCT06651177
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
T. John Winhusen, PhD
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT05912621
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
Stanford University
INTERVENTIONAL
Updated Dec 15, 2025